> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Editorial Changes Made Due to Obsolete FDA Office
- URL: https://www.fdaweb.com/editorial-changes-made-due-to-obsolete-fda-office/
- Published: 2021-03-31T12:00:00.000Z
- Updated: 2026-09-14T16:53:09.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149003

*Federal Register* notice: FDA is amending its medical device regulations to make an editorial nonsubstantive change and replace a reference to an obsolete office with updated information. The regulations specified in the notice have been revised to correct “director of the Office of Regulatory Program” to “director or Principal Deputy Director of the Office of Product Evaluation and Quality” and replace a reference to “director, Office of Compliance” with “director or deputy directors, CDRH, or the director or principal deputy director of the Office of Product Evaluation and Quality.” To view the notice, click [here](https://public-inspection.federalregister.gov/2021-06681.pdf?ref=fdaweb.com).